Press release |  

**IBA’S RADIOMED WINS FAVORABLE VERDICT IN JURY TRIAL AGAINST ONC SOLUTIONS; JURY AWARDS $200,000 IN DAMAGES**

RadioMed wins favorable verdict in jury trial protecting intellectual property.

**Bartlett, TN, Feb. 07th, 2012** - RadioMed Corporation, a subsidiary of Ion Beam Applications, S.A. has won a favorable verdict in a jury trial against ONC Solutions, Inc and John Schwamb, one of the founders of ONC Solutions, regarding the protection of RadioMed’s intellectual property. The jury agreed RadioMed has proven its case that its confidential and proprietary information was taken and used by ONC Solutions in the development of ONC Solutions’ products starting in 2007 and such use caused harm to RadioMed. Consequently, the jury awarded RadioMed $200,000 in past damages against ONC Solutions and Mr. Schwamb as fair compensation for their actions. RadioMed is prepared for any extension to this case should ONC Solutions disagree with the decision and decide to appeal this verdict.

“We are very pleased the jury recognized the importance of protecting the intellectual property associated with VISICOIL”, stated Chuck Lindley, RadioMed COO. “RadioMed has invested significant time and resources in developing this patented cancer treatment technology. We at IBA truly respect the intellectual property of other companies in the market and it is critical to our business model that we take every step needed to protect and defend ours. With this action behind us, we look forward to focusing on IBA’s mission to protect, enhance and save lives” added Lindley.

###

**About RadioMed and VISICOIL™**

RadioMed Corporation was founded in 1997 as a private corporation and became part of IBA in 2003. VISICOIL is a patented (US Patent 8,027,712) helically wound gold coil available in various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast and various other organs.

The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. VISICOIL’s flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. VISICOIL is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per US FDA cleared 510(K). For more information about VISICOIL, please visit [www.VISICOIL.com](http://www.VISICOIL.com).

**About IBA**

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Headquartered in Belgium, IBA declared revenues of about EUR 400 million in 2010. It is present in more than 40 countries in North America, Europe and Asia and employs 2100 professionals. The dosimetry activity of IBA offers a full range of innovative solutions for radiotherapy, radiodiagnostics, calibration service and imaging markers. Its measuring instruments and software enable medical physicists and radiologists to perform the necessary quality assurance and calibration procedures. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). For more information: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**Media Contact:**

Kevin Reynolds
VISICOIL Product Specialist
RadioMed Corporation Bartlett, TN.
Tel: (901) 432-7202
Kevin.reynolds@iba-group.com